It discusses investigational peptides from a laboratory research perspective and should not be interpreted as medical advice or treatment recommendations
The mean time to intensification of treatment with insulin was 7.1, 6.1 and 6.0 years for those taking one, two or three oral drugs
GLP-1 receptor agonists and dual amylin co-agonists: Emerging therapies
General handling: Always replace the pen cap after each use to protect from light and maintain sterility
It increases insulin release when blood sugar rises after meals, reduces sugar produced by the liver, and slows digestion to prevent sudden glucose spikes
Beyond gastrointestinal effects, clinical data and class-level evidence from licensed incretin agents (semaglutide, tirzepatide) have flagged concerns regarding: Heart rate elevation: Increases in resting heart rate are a recognised class effect of GLP-1 receptor agonists, documented in the SmPCs for semaglutide (Wegovy) and tirzepatide (Mounjaro)